GoodRx Holdings announced that it will now offer self‑pay pricing for Novo Nordisk’s Ozempic® pill, an oral semaglutide medication for type 2 diabetes. The new program provides a direct‑to‑consumer option for patients, with pricing tiers of $149 per month for the 1.5 mg dose, $199 per month for the 4 mg dose, and $299 per month for the 9 mg dose. The launch extends GoodRx’s Pharma Direct portfolio, adding a high‑margin prescription drug to its existing discount‑card and pharmacy‑partner services.
The move reflects GoodRx’s broader strategy to shift from a prescription‑discount platform toward a consumer‑focused digital health ecosystem that emphasizes high‑margin Pharma Direct and subscription services. In 2025, Pharma Direct revenue grew 41% year‑over‑year, while traditional prescription‑transaction revenue has been under pressure. By adding the Ozempic® pill, GoodRx aims to capture a larger share of the growing GLP‑1 market and diversify its revenue mix, positioning the company for more resilient long‑term growth.
Wendy Barnes, President and CEO of GoodRx, said, “As Novo Nordisk brings the Ozempic pill to market, we’re focused on helping patients access it with clear, transparent pricing.” Novo Nordisk’s senior vice president of marketing, Ed Cinca, added, “GoodRx helps expand access to our medicines, now including the Ozempic pill, with a clear self‑pay pricing model.” Barnes also noted, “We are building the leading, consumer‑focused digital healthcare platform in the United States. We provide easy access to price transparency and affordability solutions for medications, convenient telehealth consultations, and additional healthcare services and resources.” She further emphasized, “We believe this positions GoodRx Holdings, Inc. for stronger, more resilient long‑term growth, even as we navigate near‑term financial impacts from this transition.”
GoodRx’s recent financial performance underscores the context for this launch. In Q4 2025, the company reported earnings per share of $0.09 versus analyst expectations of $0.07, and revenue of $194.8 million versus $193.43 million expected. In Q1 2025, earnings per share were $0.03 against an estimate of $0.04, while revenue of $203.0 million slightly exceeded the $202.21 million forecast. For Q1 2026, analysts are projecting earnings per share of $0.07 and revenue of approximately $185.36 million. The introduction of the Ozempic® pill is expected to contribute to the high‑margin segment that has been a key driver of GoodRx’s recent revenue growth, while the company continues to manage near‑term financial impacts associated with the strategic shift.
The addition of a high‑margin prescription drug to GoodRx’s portfolio is a significant step in its transition toward a more diversified, consumer‑centric business model. By offering the Ozempic® pill at transparent self‑pay prices, GoodRx can attract patients who might otherwise rely on insurance coverage, thereby expanding its customer base and reinforcing its position in the competitive GLP‑1 market. While the immediate financial impact of the launch is modest relative to the company’s overall revenue, the move signals a broader commitment to scaling high‑margin Pharma Direct services, which could enhance profitability and support long‑term growth as the company navigates evolving market dynamics.
The content on EveryTicker is for informational purposes only and should not be construed as financial or investment advice. We are not financial advisors. Consult with a qualified professional before making any investment decisions. Any actions you take based on information from this site are solely at your own risk.